The TIMER 2.0 database showed that compared with normal samples, EIF2S2 was overexpressed in most types of cancer, including HCC, colon cancer, lung adenocarcinoma, prostate cancer, endometrial cancer, breast invasive cancer, etc. (Figure 1A). This evidence concerns the gene EIF2S2 and hepatocellular carcinoma.